EFTA01092032Set 9
25p12,760w
GROUP
EQUITY RESEARCH
INDUSTRY REPORT
.►uly S. 2013
Regenerative Cell Therapy: Autologous versus allogeneic is the wrong question?
It's pre-clinical, manufacturing,
and clinical data that drive safety.
Companies ... science. Mesoblast and Athersys have reported no immune responses associated with their
allogeneic cell therapies. In fact, Pluristem, Mesoblast, and Athersys use different cell types and process
them differently. Mesoblast ... patient. We consider the purifying of the cells a
technique used by most cell therapy products as a manipulation. For example both Baxter and NeoStem,
enrich their products for CD34
https://www.justice.gov/epstein/files/DataSet%209/EFTA01092032.pdf
EFTA01110707Set 9
22p7,189w
Canavan Disease
FUNDING
HISTORY
GRANT SUPPORT:
Principal Investigator
Funding Agency: UMDNJ Foundation
Title: Stem Cell Therapy for Canavan Disease
Project Dates: 04/01/13 — 03/31/14
Total Direct Costs: $25,000
Funding Agency ... 01/31/14
Total Direct Costs: $100,000
Funding Agency: Jacob's Cure
Title: human Stem Cell Therapy for Canavan Disease
Project Dates: 08/01/12 — 07/31/13
Total Direct Costs: $100,000
Funding Agency ... Funding Agency: Canavan Research Illinois & Jacob's Cure, NY
Title: Analysis of Stem Cell Therapy in the Tremor Rat Model of Canavan Disease
Project Dates: 06/01/03- 05/31/07
Total Direct Costs
https://www.justice.gov/epstein/files/DataSet%209/EFTA01110707.pdf
EFTA00966599Set 9
2013-08-163p991w
From: Steven Victor MD <1
To:
Subject: Fwd: Maxim Group: Regenerative Cell Therapy - Osiris Graffix highlights a Back Door. Is
there an Achilles heel in Cell Therapy with a KISS ... admin
Sent Fri, Aug 16, 2013 8:14 am
Subject: FW: Maxim Group: Regenerative Cell Therapy - Osiris Graffix highlights a Back Door. Is there an Achilles heel in
Cell Therapy ... Jason Kolbert
Date: Friday, August 16, 2013 7:44 AM
Subject: Maxim Group: Regenerative Cell Therapy - Osiris Graffix highlights a Back Door. Is there an Achilles heel in
Cell Therapy
https://www.justice.gov/epstein/files/DataSet%209/EFTA00966599.pdf
EFTA01092057Set 9
2013-08-165p2,594w
GROUP
EQUITY RESEARCH
INDUSTRY REPORT
August 16, 2013
Regenerative Cell Therapy: Osiris Graffix highlights a Back Dour. Is there an Achilles heel in Cell
Therapy with a KISSUtti, a simple ... regulatory pathway and try to make sense of
what implications does it have in cell therapy space?
nK 1 > The FDA has allowed this "back door" as a pathway into ... MAPC stem cells, under 361 as well. This
opens the question what other cell therapy products can come to the
market under 361. For example we believe the stromal vascular
https://www.justice.gov/epstein/files/DataSet%209/EFTA01092057.pdf
EFTA01092027Set 9
2013-10-125p2,524w
GROUP
EQUITY RESEARCH
INDUSTRY REPORT
October 12 2013
Regenerative Cell Therapy
Osiris Grafix: Trick or Treat?
Grafix Goes Through the Front
Door
Companies mentioned include.•
Athersys, Inc. (ATHX ... report), trying
Osiris (OSIR) — $14.51 — NR to make sense of its implications in the cell therapy space.
Pfizer (PFE) — $30.40 — NR Yesterday, Osiris clarified the regulatory status.
Pluristem (PSTI ... Athersys' MAPC stem cells, under 361
as well. This opens the question about other cell therapy products
that can come to the market under 361.
> Following Osiris' release, issued
https://www.justice.gov/epstein/files/DataSet%209/EFTA01092027.pdf
EFTA00964821Set 9
2013-07-084p548w
From: Steven Victor MD <I
To:
Subject: Fwd: Maxim Group: Regenerative Cell Therapy: Autologous versus allogeneic is the wrong question?
It's pre-clinical, manufacturing, and clinical data that drive ... admin
Sent: Mon, Jul 8, 2013 8:10 am
Subject: FW: Maxim Group: Regenerative Cell Therapy: Autologous versus allogeneic is the wrong question? It's pre-clinical,
manufacturing, and clinical ... Monday, July 8, 2013 8:05 AM
To: admin
Subject: FW: Maxim Group: Regenerative Cell Therapy: Autologous versus allogeneic is the wrong question? It's pre-clinical,
manufacturing, and clinical
https://www.justice.gov/epstein/files/DataSet%209/EFTA00964821.pdf
EFTA01853994Set 10
2014-07-309p2,571w
been looking for the next wave. and I think the biologics,
particularly stem-cell therapy and enhancement of the healing properties, will be it."
EFTA_R1_00249917
EFTA01853997 ... received, from a Colorado-based biologics company. illustrates the wide
spectrum of stem-cell therapies NFL players are using. The product in the vial didn't contain
the player ... saying: 'You can't bargain with Mother Nature.' The
biologics. the stem-cell therapy, is the revelation that may change that."
TAGS:
Chris Johnson
Dr. ManiAnz
DidarnesAndrews
Peyton Manning
Stein
https://www.justice.gov/epstein/files/DataSet%2010/EFTA01853994.pdf